When chemotherapy stops working for bladder cancer patients, a new class of drugs is rewriting survival odds in ways that would have seemed improbable just a few years ago. The combination of enfortumab vedotin (sold as Padcev) and pembrolizumab (Keytruda) has doubled median overall survival in advanced urothelial cancer to 31.5 months, compared with 16.1 months for chemotherapy alone, according to the EV-302 trial published in the New England Journal of Medicine. For the estimated 83,000 Americans diagnosed with bladder cancer each year — and for caregivers already navigating the cognitive and emotional toll of supporting a loved one through treatment — this represents a genuine shift in what is possible. But Padcev and Keytruda are not the only developments worth understanding. A tiny, pretzel-shaped implant called TAR-200 (brand name Inlexzo) eliminated tumors in 82 percent of patients with a form of bladder cancer that had stopped responding to the standard BCG therapy, earning FDA approval in September 2025.
Meanwhile, other targeted therapies and novel drug-delivery systems approved in 2025 and under study in 2026 are expanding options for patients at nearly every stage of the disease. This article walks through what these drugs are, how they work, who they help, and what limitations caregivers and patients should keep in mind. For readers of this site, the connection between cancer treatment and brain health is not abstract. Chemotherapy-related cognitive decline — sometimes called chemo brain — affects memory, attention, and executive function, and it is a particular concern for older adults already at risk for dementia. Treatments that reduce or replace the need for traditional chemotherapy may carry meaningful implications for preserving cognitive function, a topic we will return to later.
Table of Contents
- What Is the Bladder Cancer Drug That Works When Chemo Fails?
- How Padcev and Keytruda Are Changing Survival Before and After Surgery
- The Tiny Implant Eliminating Bladder Tumors Without Surgery
- Comparing the New Bladder Cancer Treatment Options
- Cognitive Concerns — What Bladder Cancer Treatment Means for Brain Health
- What Zusduri and Other Approvals Mean for Early-Stage Patients
- Where Bladder Cancer Treatment Is Heading in 2026 and Beyond
- Conclusion
- Frequently Asked Questions
What Is the Bladder Cancer Drug That Works When Chemo Fails?
The short answer is enfortumab vedotin, an antibody-drug conjugate that targets a protein called Nectin-4 found on the surface of most bladder cancer cells. Unlike traditional chemotherapy, which attacks rapidly dividing cells indiscriminately, enfortumab vedotin delivers a potent cell-killing agent directly to tumor cells, sparing more healthy tissue in the process. When combined with the immune checkpoint inhibitor pembrolizumab, which helps the immune system recognize and attack cancer, the results have been striking. In the landmark EV-301 trial, patients whose cancer had progressed after both platinum-based chemotherapy and checkpoint inhibitor therapy saw median overall survival of 12.88 months with enfortumab vedotin alone, compared with 8.97 months on standard chemotherapy — a statistically significant improvement with a hazard ratio of 0.70. What makes this combination particularly notable is its performance as a first-line treatment, not just a last resort.
The EV-302 trial showed that previously untreated patients with advanced urothelial cancer who received Padcev plus Keytruda achieved progression-free survival of 12.5 months versus 6.3 months with chemotherapy. That is not a marginal improvement — it is a doubling. For context, cisplatin-based chemotherapy had been the standard first-line treatment for advanced bladder cancer for decades, and no regimen had meaningfully surpassed it until now. The comparison matters for patients and families weighing treatment decisions. Traditional platinum-based chemotherapy comes with well-documented side effects including neuropathy, kidney damage, severe nausea, and the cognitive fog that so many caregivers on this site know firsthand. Enfortumab vedotin has its own side effect profile — skin reactions, peripheral neuropathy, and blood sugar changes among them — but the overall toxicity pattern differs, and for many patients, the tradeoff favors the newer approach.
How Padcev and Keytruda Are Changing Survival Before and After Surgery
Beyond advanced disease, the Padcev-Keytruda combination is now reshaping treatment for patients with muscle-invasive bladder cancer who are heading into surgery. In November 2025, the FDA approved the combination for cisplatin-ineligible patients in the perioperative setting — meaning before and after surgical removal of the bladder or tumor. This approval was based on data showing the regimen reduced the risk of death by 50 percent compared with surgery alone. The KEYnotE-B15 trial, with updated results presented at ASCO GU 2026, reinforced this finding: estimated 24-month overall survival reached 86.9 percent with enfortumab vedotin plus pembrolizumab, compared with 81.3 percent with chemotherapy. Perhaps more telling, the 2-year event-free survival — meaning the percentage of patients who had not experienced disease recurrence, progression, or death — was 74.7 percent with the combination versus 39.4 percent with surgery alone.
This is the first non-platinum regimen to outperform cisplatin-based chemotherapy in muscle-invasive bladder cancer in nearly 25 years. However, this does not mean the combination is appropriate for every patient. Those who are eligible for cisplatin and can tolerate it may still be offered platinum-based chemotherapy, particularly if their oncologist has concerns about specific side effects associated with enfortumab vedotin, such as peripheral neuropathy or hyperglycemia. Patients with pre-existing diabetes or significant nerve damage should have a frank conversation with their care team about which regimen carries fewer risks for their particular situation. The approval specifically targets cisplatin-ineligible patients for a reason — it fills a gap where no good perioperative option previously existed.
The Tiny Implant Eliminating Bladder Tumors Without Surgery
For patients with non-muscle-invasive bladder cancer — an earlier stage where the tumor has not grown into the deeper muscle layers of the bladder wall — a completely different kind of innovation arrived in 2025. TAR-200, approved by the FDA on September 9, 2025, under the brand name Inlexzo, is a small, pretzel-shaped device that a physician inserts into the bladder through a catheter. Once in place, it slowly releases the chemotherapy drug gemcitabine over a three-week period, allowing the medication to penetrate deeply into the bladder wall in a way that traditional intravesical treatments cannot match. The results from the phase IIb SunRISe-1 trial were remarkable. Among 85 patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer — people for whom the standard immunotherapy treatment had stopped working — TAR-200 eliminated tumors in 70 patients, an 82.4 percent complete response rate. The median duration of that response was 25.8 months, and nearly half of patients remained cancer-free at one year.
There were no treatment-related deaths, and adverse events were described as manageable. Consider what this means in practical terms. The previous standard of care for BCG-unresponsive bladder cancer was often radical cystectomy — complete surgical removal of the bladder. That is a life-altering operation with profound impacts on quality of life, continence, and independence, especially for older adults. For a patient in their seventies or eighties who may already be managing cognitive decline, the prospect of major surgery and its associated delirium risk is daunting. Inlexzo offers a bladder-preserving alternative with a treatment schedule of every three weeks for six months, then four times per year for two years. It does not eliminate the need for ongoing monitoring, but it can eliminate the need for losing the bladder entirely.
Comparing the New Bladder Cancer Treatment Options
With multiple new approvals arriving in rapid succession, patients and caregivers face a more complex but ultimately more hopeful treatment landscape. Understanding the differences between these options matters. For advanced or metastatic bladder cancer, the Padcev-Keytruda combination is now the leading option, particularly for patients who cannot tolerate cisplatin. Its survival advantage over chemotherapy is substantial and consistent across multiple trials. For patients with HER2-positive bladder cancer specifically, disitamab vedotin (marketed as Aidixi) represents another targeted option, achieving overall survival of 31.5 months compared with 16.9 months for platinum-based chemotherapy in first-line treatment.
The catch is that HER2 positivity must be confirmed through testing, and not all bladder cancers express this protein — so Aidixi serves a narrower population. For non-muscle-invasive disease, the choice between Inlexzo and another 2025 approval, Zusduri, depends on the specific type and risk level. Zusduri, approved by the FDA on June 12, 2025, delivers mitomycin via a reverse thermal gel that adheres to the bladder wall for up to six hours. It is indicated for recurrent low-grade, intermediate-risk non-muscle-invasive bladder cancer — a different patient population than the high-risk, BCG-unresponsive group for which Inlexzo was approved. Choosing between these is not a matter of preference; it is a matter of matching the right drug to the right disease profile. Patients should expect their oncologist to explain which category their cancer falls into and why a particular treatment is recommended.
Cognitive Concerns — What Bladder Cancer Treatment Means for Brain Health
For readers of a dementia care and brain health site, the connection between cancer treatment and cognition deserves direct attention. Chemotherapy-related cognitive impairment is not a myth or a minor inconvenience. Research consistently shows that platinum-based chemotherapy can cause measurable declines in memory, processing speed, and executive function — effects that may persist for months or years after treatment ends. For older adults who may already have subclinical neurodegenerative changes, this added insult can tip the balance toward noticeable impairment. This is one reason the shift toward targeted therapies and immunotherapies matters beyond survival statistics. Drugs like enfortumab vedotin and pembrolizumab work through different mechanisms than traditional chemotherapy, and while they are not free of neurological side effects — peripheral neuropathy is a known risk with enfortumab vedotin — the kind of diffuse central nervous system toxicity associated with platinum agents appears to be less common.
That said, this is an area where the data is still evolving. No large-scale trial has yet directly compared cognitive outcomes between Padcev-Keytruda and cisplatin-based regimens. Caregivers should be aware of a practical limitation: if the person they are supporting already has a dementia diagnosis or significant cognitive impairment, treatment decisions become more complex. Informed consent, treatment adherence, managing side effects, and recognizing complications all require cognitive capacity. The care team should include a discussion about goals of care, quality of life, and whether the person with dementia has an advance directive that addresses cancer treatment. These are not easy conversations, but they are essential ones.
What Zusduri and Other Approvals Mean for Early-Stage Patients
The approval of Zusduri in June 2025 specifically addresses a population that often falls through the cracks of cancer drug development: patients with recurrent low-grade, intermediate-risk non-muscle-invasive bladder cancer. These patients have tumors that are unlikely to become immediately life-threatening but are prone to coming back after treatment, leading to an exhausting cycle of surveillance cystoscopies and repeat procedures. Zusduri’s reverse thermal gel technology keeps mitomycin in contact with the bladder wall for up to six hours, improving drug exposure without requiring an implanted device.
For older adults managing this kind of recurrent, lower-risk bladder cancer alongside cognitive concerns, Zusduri offers a less burdensome treatment experience than repeated surgical resections. Still, it is important to recognize that this approval covers a specific risk category. Patients with high-grade tumors, carcinoma in situ, or BCG-unresponsive disease will need different approaches — Inlexzo, the Padcev-Keytruda combination, or potentially radical surgery depending on the stage and their overall health.
Where Bladder Cancer Treatment Is Heading in 2026 and Beyond
The pace of progress in bladder cancer treatment over the past two years has been extraordinary by historical standards. The field went from relying on platinum-based chemotherapy that had been essentially unchanged since the 1980s to having multiple FDA-approved targeted therapies, immunotherapy combinations, and novel drug-delivery systems.
Research presented at ASCO GU 2026, including the KEYNOTE-B15 data, suggests this momentum is continuing, with ongoing trials exploring new combinations, earlier-stage uses for existing drugs, and biomarker-driven approaches to match patients with the treatments most likely to work for them. For patients, caregivers, and families navigating both cancer and cognitive health concerns, the practical takeaway is that the conversation with the oncology team should now include questions it might not have included five years ago: Is there a targeted therapy option? Can we avoid or reduce platinum-based chemotherapy? What are the cognitive side effect profiles of the recommended regimen? And for those managing bladder cancer alongside dementia, what does the treatment burden look like in terms of appointments, monitoring, and caregiver demands? The answers will vary by individual, but the range of options has never been wider.
Conclusion
Bladder cancer treatment has undergone a genuine transformation. The combination of enfortumab vedotin and pembrolizumab has doubled survival in advanced disease and is now proving its worth before and after surgery. TAR-200, the tiny intravesical implant sold as Inlexzo, is eliminating tumors in more than 80 percent of patients who had run out of standard options, preserving bladders that would have otherwise been surgically removed.
And additional approvals like Zusduri and disitamab vedotin are filling gaps for specific patient populations that chemotherapy served poorly. For those reading this through the lens of brain health and dementia care, these developments carry a particular significance. Every treatment that reduces reliance on traditional chemotherapy is potentially a treatment that better preserves cognitive function — though more research is needed to confirm this hope with hard data. In the meantime, the most important step for patients and caregivers is to ask the oncology team about all available options, including the newer targeted therapies and drug-delivery systems, and to ensure that cognitive health is part of the treatment planning conversation from the start.
Frequently Asked Questions
What is enfortumab vedotin (Padcev) and how does it differ from traditional chemotherapy?
Enfortumab vedotin is an antibody-drug conjugate that targets the Nectin-4 protein on bladder cancer cells, delivering a cell-killing agent directly to tumors rather than attacking all rapidly dividing cells indiscriminately. Combined with the immunotherapy pembrolizumab (Keytruda), it achieved median overall survival of 31.5 months versus 16.1 months for chemotherapy in the EV-302 trial.
Who is eligible for the Padcev-Keytruda combination?
The combination is approved for advanced urothelial cancer as first-line treatment and for patients whose cancer has progressed after platinum chemotherapy. In the perioperative setting, the November 2025 approval specifically covers cisplatin-ineligible patients with muscle-invasive bladder cancer. Eligibility depends on cancer stage, prior treatments, and individual health factors.
What is TAR-200 (Inlexzo) and how does it work?
Inlexzo is a small, pretzel-shaped device inserted into the bladder via catheter that releases the drug gemcitabine slowly over three weeks. It was FDA-approved in September 2025 for BCG-unresponsive high-risk non-muscle-invasive bladder cancer and eliminated tumors in 82.4 percent of patients in the SunRISe-1 trial, with a median response duration of 25.8 months.
Can bladder cancer treatment cause cognitive decline?
Platinum-based chemotherapy is associated with measurable declines in memory, processing speed, and executive function — often called chemo brain. Newer targeted therapies like enfortumab vedotin work through different mechanisms and may carry different cognitive risk profiles, though head-to-head cognitive comparisons have not yet been conducted in large trials.
What is the difference between Inlexzo and Zusduri?
They treat different patient populations. Inlexzo is approved for high-risk, BCG-unresponsive non-muscle-invasive bladder cancer and uses an implanted device to release gemcitabine. Zusduri, approved in June 2025, treats recurrent low-grade, intermediate-risk non-muscle-invasive bladder cancer and delivers mitomycin via a thermal gel that adheres to the bladder wall.
Should someone with dementia undergo bladder cancer treatment?
This depends on the stage of both the cancer and the dementia, the person’s goals of care, and the available treatment options. The care team should discuss treatment burden, cognitive side effects, and quality of life. An advance directive addressing cancer treatment can help guide decisions if cognitive capacity is declining.
